Are Parkinson disease patients protected from some but not all cancers?

There is substantial evidence based on well designed epidemiologic studies for low cancer rates in patients with Parkinson disease (PD). This risk reduction cannot be attributed to the recognized low life-long incidence of smoking in patients with PD, as not only smoking-related cancers but also non-smoking-related ones are less common in PD. Whereas the risk for most cancers appears to be relatively low in patients with PD, breast cancer and melanomas occur more frequently in the PD population as compared with controls. The relationship between this peculiar pattern of cancer rates and PD might be related to the involvement of common genes in both diseases. Mutations in parkin gene, for example, have been reported in several types of cancer. Furthermore, genes involved in familial forms of PD appear to be abnormally expressed in cancers. Thus, parkin and PINK1 might be tumor suppressor genes, whereas DJ-1 is an oncogene. Cell survival signals may differ owing to mutated genes and represent two opposite extremes such as cell proliferation in cancer and cell death due to apoptosis in PD. Unraveling the link between PD and cancer may open a therapeutic window for both diseases.

[1]  A. Davies,et al.  Organization, expression and polymorphism of the human persyn gene. , 1998, Human molecular genetics.

[2]  G. Xiao,et al.  Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. , 1997, Cancer research.

[3]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[4]  B. Liu,et al.  Effects of Estrogen and Related Agents upon Methamphetamine-Induced Neurotoxicity within an Impaired Nigrostriatal Dopaminergic System of Ovariectomized Mice , 2006, Neuroendocrinology.

[5]  D. Maraganore,et al.  Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study , 2005, Movement disorders : official journal of the Movement Disorder Society.

[6]  J. Trojanowski,et al.  Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary , 2000, Cancer.

[7]  M. Netsky,et al.  Prevalence of neoplasms and causes of death in paralysis agitans A necropsy study , 1973, Neurology.

[8]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[9]  J. Jankovic,et al.  Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation , 2005, Annals of neurology.

[10]  J. Olsen,et al.  Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease , 2006, Epidemiology.

[11]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[12]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[13]  Vijayalaxmi,et al.  Melatonin: from basic research to cancer treatment clinics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Hofman,et al.  Smoking and Parkinson's disease: Systematic review of prospective studies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[15]  D. Dluzen,et al.  Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system , 2001, Neuroscience.

[16]  K. Takahashi,et al.  Epidemiology of Parkinson's disease in a Japanese city. , 1983, Archives of neurology.

[17]  H. Chern,et al.  The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese , 2001, Neurology.

[18]  B. Przybilla,et al.  Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. , 1997, Journal of the American Academy of Dermatology.

[19]  B. Manyam,et al.  Safety of Long‐term Levodopa Therapy in Malignant Melanoma , 1994, Clinical neuropharmacology.

[20]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[21]  C. Croce,et al.  Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Tianhong Pan,et al.  Valproic acid‐mediated Hsp70 induction and anti‐apoptotic neuroprotection in SH‐SY5Y cells , 2005, FEBS letters.

[23]  C. Croce,et al.  Alterations of the Tumor Suppressor Gene Parkin in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[24]  T. Stewart,et al.  Breast cancer in female flight attendants , 1995, The Lancet.

[25]  L. Sessa,et al.  Physical map of the D6S149-D6S193 region on chromosome 6Q27 and its involement in benign surface epithelial ovarian tumours , 1998, Oncogene.

[26]  J. Siple,et al.  Levodopa Therapy and the Risk of Malignant Melanoma , 2000, The Annals of pharmacotherapy.

[27]  K. Westlund,et al.  CANCER AS A CAUSE OF DEATH AMONG PATIENTS WITH OTHER CHRONIC DISEASES , 1956 .

[28]  T. Mak,et al.  DJ-1, a novel regulator of the tumor suppressor PTEN. , 2005, Cancer cell.

[29]  F. Speizer,et al.  Cigarette smoking and the incidence of Parkinson's disease in two prospective studies , 2001, Annals of neurology.

[30]  J. Jankovic,et al.  Genetic testing in Parkinson disease: promises and pitfalls. , 2006, Archives of neurology.

[31]  Jacqueline Whetteckey,et al.  Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? , 2003, Parkinsonism & related disorders.

[32]  D. Goldstein,et al.  UCHL1 is a Parkinson's disease susceptibility gene. , 2004 .

[33]  R. Mayeux,et al.  Smoking and Parkinson’s disease in twins , 2002, Neurology.

[34]  J. Kincannon,et al.  The physiology of pigmented nevi. , 1999, Pediatrics.

[35]  B. Vastag.  HSP-90 inhibitors promise to complement cancer therapies , 2006, Nature Biotechnology.

[36]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[37]  Y. Pawitan,et al.  Risk and protective factors for Parkinson's disease: A study in Swedish twins , 2005, Annals of neurology.

[38]  C. Klein,et al.  Alterations in the common fragile site gene Parkin in ovarian and other cancers , 2003, Oncogene.

[39]  L. Santambrogio,et al.  Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated parkinson's disease , 1991, Journal of Neurology.

[40]  Mortality cancer risk in parkinsonian patients: a population-based study. , 1999, Neurology.

[41]  F Laden,et al.  Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. , 2001, Journal of the National Cancer Institute.

[42]  D. Abramson,et al.  Choroidal melanoma and levodopa. , 1984, JAMA.

[43]  M. Farrer,et al.  Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries , 2006, Movement disorders : official journal of the Movement Disorder Society.

[44]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[45]  J. Jankovic,et al.  Genetic analysis of LRRK2 mutations in patients with Parkinson disease , 2006, Journal of the Neurological Sciences.

[46]  B. Müller-Myhsok,et al.  A susceptibility locus for Parkinson's disease maps to chromosome 2p13 , 1998, Nature Genetics.

[47]  M. Karásek,et al.  Melatonin in humans. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[48]  M. Wick,et al.  Levodopa therapy and malignant melanoma. , 1978, JAMA.

[49]  Hreinn Stefánsson,et al.  A susceptibility gene for late‐onset idiopathic Parkinson's disease , 2002, Annals of neurology.

[50]  J. Jankovic,et al.  A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. , 2007, Archives of neurology.

[51]  C. C. Johnson,et al.  Parkinson's disease and its comorbid disorders , 1994, Neurology.

[52]  S. Scherer,et al.  Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. , 1996, Oncogene.

[53]  J. Jankovic,et al.  Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. , 2006, Archives of neurology.

[54]  T. Mak,et al.  Tumours and tremors: how PTEN regulation underlies both , 2006, British Journal of Cancer.

[55]  J. Olsen,et al.  Occurrence of different cancers in patients with Parkinson's disease , 1995, BMJ.

[56]  J. Olsen,et al.  Atypical cancer pattern in patients with Parkinson's disease , 2004, British Journal of Cancer.

[57]  Y. Minami,et al.  Mortality and cancer incidence in patients with Parkinson's disease , 2000, Journal of Neurology.

[58]  M. Quik.  Smoking, nicotine and Parkinson's disease , 2004, Trends in Neurosciences.

[59]  B. Ritz,et al.  Circulating Melatonin Levels: Possible Link Between Parkinson’s Disease and Cancer Risk? , 2006, Cancer Causes & Control.

[60]  T. Di Paolo,et al.  Differential Protective Properties of Estradiol and Tamoxifen against Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity in Mice , 2006, Neuroendocrinology.

[61]  L. J. Doshay.  Problem situations in the treatment of paralysis agitans. , 1954, Journal of the American Medical Association.

[62]  L. Kurland,et al.  A case‐control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease , 1987, Neurology.

[63]  J. Jankovic,et al.  Low cancer rates among patients with Parkinson's disease , 1985, Annals of neurology.

[64]  J. Jankovic,et al.  Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. , 2005, Biochemical and biophysical research communications.

[65]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[66]  Fang Wang,et al.  Parkin gene alterations in hepatocellular carcinoma , 2004, Genes, chromosomes & cancer.

[67]  M. Mattson,et al.  p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism , 2002, Annals of neurology.

[68]  J. Manson,et al.  Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. , 1999, Journal of the National Cancer Institute.

[69]  T. Dawson,et al.  To die or grow: Parkinson's disease and cancer , 2005, Trends in Neurosciences.

[70]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[71]  A J Lees,et al.  Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[72]  Bonifati,et al.  Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.

[73]  R. Sandyk.  Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland. , 1992, The International journal of neuroscience.

[74]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[75]  R. Godwin-Austen,et al.  Smoking and Parkinson's disease. , 1982, Journal of neurology, neurosurgery, and psychiatry.

[76]  J. Olsen.  Avoidable cancers in the Nordic countries. Aims and background. , 1997, APMIS. Supplementum.

[77]  T. Tsunoda,et al.  Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. , 2001, Cancer research.

[78]  D. Maraganore,et al.  UCHL1 is a Parkinson's disease susceptibility gene , 2004, Annals of neurology.

[79]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[80]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[81]  D. Morens,et al.  Cigarette smoking and protection from Parkinson's disease , 1995, Neurology.

[82]  M. Marmot,et al.  Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? , 1995, Journal of neurology, neurosurgery, and psychiatry.

[83]  Yusuke Nakamura,et al.  Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway , 2001, Oncogene.

[84]  D. Maraganore,et al.  Nonfatal Cancer Preceding Parkinson’s Disease: A Case-Control Study , 2002, Epidemiology.